Marksans Pharma Q1 FY27 Results Analysis: EBITDA Margin Expands 919 bps, Revenue Surges 35.6% YoY

Marksans Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 8,407.96 Cr (+35.61% YoY) and PAT growth of +173.89% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Marksans Pharma delivered 35.6% YoY revenue growth and a 919 bps EBITDA margin expansion to 25.34%, well above the FY27 guidance of 20-21%. The beat was driven by operating leverage and cost management, though standalone revenue was flat, and the consolidated growth relied heavily on subsidiaries.

Key Investment Insights

Key Positives

• Revenue grew 35.6% YoY to Rs.8,407.96 Cr.
• EBITDA margin expanded 919 bps YoY to 25.34%, above management's FY27 guidance of 20-21%.
• PAT grew 173.9% YoY to Rs.1,594.07 Cr.
• All major cost lines declined as a percentage of revenue YoY.
• Standalone EBITDA margin improved to 25.56% from 21.91% a year ago.

Risk Factors

• Standalone revenue was virtually flat YoY at +0.45%, indicating consolidated growth is primarily driven by subsidiaries.
• Elevated other income (Rs.254.04 Cr) was not itemized; its sustainability is uncertain.